- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed/refractory multiple myeloma
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 364KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 63KB)
Pomalidomide – July 2023
Pomalidomide: Capsule 1 mg, Capsule 2 mg; PomolideTM
Last updated
27 October 2023